Telis Bioscience is an American biotechnology company based in Cambridge, Massachusetts.
History
Telis was founded in 2019 by Grigory Khimulya and Kyle Fish.[1][2]
In December 2021, Telis pivoted to focus on developing a COVID-19 vaccine under a new name, Alvea, which launched in January 2022.[3]
Organization
Telis received $2 million from Alameda Research.[4]
Personnel
| Name | Position | Notes |
|---|---|---|
| Grigory Khimulya | Co-founder & Chief Executive Officer | - |
| Kyle Fish | Co-founder & Chief Technology Officer | - |
External links
Telis Bioscience - Crunchbase Company Profile & Funding. Crunchbase. Retrieved March 27, 2023, from https://www.crunchbase.com/organization/telis-bioscience ↩︎
Grigory Khimulya [@grigonomics]. (2020, September 23). “Life update: for the past year @fish_kyle3 and I have been building Telis Bioscience, a venture-backed biotech company in Cambridge, MA engineering high-impact protein therapeutics . We’re hiring! (1/5)” [Tweet]. Twitter. http://archive.today/2023.03.27-011210/https://twitter.com/grigonomics/status/1308768978756567042 ↩︎
McGrath, K. (2022, February 16). Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants. PR Newswire. https://web.archive.org/web/20220513024500/https://www.prnewswire.com/news-releases/alvea-launches-scalable-shelf--stable-dna-vaccine-development-against-new-sars-cov-2-variants-301483557.html ↩︎
Ashworth, L. (2022, December 19). How to spend a million dollars, by Sam Bankman-Fried. Financial Times. http://archive.today/2023.01.11-055404/https://www.ft.com/content/9a3b4b78-b18b-4d1f-b28b-05a73525aa61 ↩︎
